Pancreatic Cancer Research

ResearcherTongji UniversityNo recent work listed

Ping Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7815-7532; OpenAlex author ID A5100400294. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 3 papers · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 3 papers

Papers 10

  1. Systemic Chemotherapy With or Without Hepatic Arterial Infusion Chemotherapy for Liver Metastases From Pancreatic Cancer: A Propensity Score Matching Analysis. Co-author DOI 10.1016/j.clcc.2022.10.007↗
  2. Metabolomics-based discovery of XHP as a CYP3A4 inhibitor against pancreatic cancer. Co-author DOI 10.3389/fphar.2023.1164827↗
  3. Developments and challenges in neoadjuvant therapy for locally advanced pancreatic cancer. Last author DOI 10.3748/wjg.v29.i35.5094↗
  4. Novel compound C150 inhibits pancreatic cancer through induction of ER stress and proteosome assembly. First author DOI 10.3389/fonc.2022.870473↗
  5. Inhibition of pancreatic cancer stem cells by Rauwolfia vomitoria extract. First author DOI 10.3892/or.2018.6713↗
  6. Effect of p53 on pancreatic cancer-glucose tolerance abnormalities by regulating transglutaminase 2 in resistance to glucose metabolic stress. Co-author DOI 10.18632/oncotarget.19402↗
  7. MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3. Last author DOI 10.1007/s13277-016-5295-4↗
  8. Long non-coding RNA UCA1 promotes the tumorigenesis in pancreatic cancer. Co-author DOI 10.1016/j.biopha.2016.08.041↗
  9. Targeting Epithelial-Mesenchymal Transition for Identification of Inhibitors for Pancreatic Cancer Cell Invasion and Tumor Spheres Formation. Co-author DOI 10.1371/journal.pone.0164811↗
  10. Genome-wide screening reveals an EMT molecular network mediated by Sonic hedgehog-Gli1 signaling in pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0043119↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bo Zhou · 1 shared paper, 2023 · strength 0.26
  2. Tao Wang · 2 shared papers, 2016–2022 · strength 0.25
  3. Ruochen Dong · 2 shared papers, 2016–2018 · strength 0.20
  4. Qi Chen · 1 shared paper, 2022 · strength 0.19
  5. Zhuchen Yan · 1 shared paper, 2023 · strength 0.18
  6. Weidong Ma · 1 shared paper, 2023 · strength 0.18
  7. Tongguo Si · 1 shared paper, 2023 · strength 0.18
  8. Huaqiang Ouyang · 1 shared paper, 2023 · strength 0.18
  9. Anna Sandström Gerdtsson · 1 shared paper, 2023 · strength 0.18
  10. Donglin Liu · 1 shared paper, 2023 · strength 0.18
  11. Junning Zhao · 1 shared paper, 2023 · strength 0.17
  12. Yuting Yang · 1 shared paper, 2023 · strength 0.17
  13. Qi Chen · 1 shared paper, 2018 · strength 0.14
  14. Qiaoming Zhi · 1 shared paper, 2016 · strength 0.07
  15. Weihua Chang · 1 shared paper, 2016 · strength 0.07
  16. Xiao Hua Su · 1 shared paper, 2017 · strength 0.06
  17. Qiwen Ben · 1 shared paper, 2017 · strength 0.06
  18. Wei‐Guang Li · 1 shared paper, 2017 · strength 0.06
  19. Xiangyi He · 1 shared paper, 2017 · strength 0.06
  20. Yi Zang · 1 shared paper, 2017 · strength 0.06
  21. Yaozong Yuan · 1 shared paper, 2017 · strength 0.06
  22. Weiyan Yao · 1 shared paper, 2017 · strength 0.06
  23. Kishore Polireddy · 1 shared paper, 2016 · strength 0.06
  24. Qi Chen · 1 shared paper, 2016 · strength 0.06
  25. Chuangao Xie · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.